Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06436027 · ClinicalTrials.gov registry record
Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
A clinical trial, sponsored by Paris Translational Research Center for Organ Transplantation.
- Completed
- Registry status
- 496
- Enrollment target
NCT06436027 is a clinical trial that has completed, run by Paris Translational Research Center for Organ Transplantation. The registered enrollment target is 496 participants.
The verdict
NCT06436027 has completed, sponsored by Paris Translational Research Center for Organ Transplantation.
- COMPLETED
- Registry status
- 496 participants
- Enrollment target
Study Summary
The goal of this observational study is to develop and validate a molecular heart rejection diagnostic system based on targeted transcriptome as a novel monitoring companion tool for heart allograft precision diagnostics applicable to formalin-fixed paraffin-embedded endomyocardial biopsies. The primary outcome will be the biopsy-proven rejection, that will be predicted with molecular classifiers (cellular and antibody-mediated rejection scores).
Interventions
- DIAGNOSTIC_TEST Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2023-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06436027
The ClinicalTrials.gov registry entry for NCT06436027 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Paris Translational Research Center for Organ Transplantation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling is the first listed.
NCT06436027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06436027 about?
NCT06436027 is a clinical study titled "Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.". The goal of this observational study is to develop and validate a molecular heart rejection diagnostic system based on targeted transcriptome as a novel monitoring companion tool for heart allograft precision diagnostics applicable to formalin-fixed paraffin-embedded endomyocardial biopsies. The pr...
What is the current status of trial NCT06436027?
This trial is currently completed. The enrollment target is 496 participants. The study started on 2021-11-10. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT06436027?
The interventions under investigation include: Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06436027?
This trial is sponsored by Paris Translational Research Center for Organ Transplantation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.